Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1361823rdf:typepubmed:Citationlld:pubmed
pubmed-article:1361823lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1361823lifeskim:mentionsumls-concept:C0020443lld:lifeskim
pubmed-article:1361823lifeskim:mentionsumls-concept:C0024027lld:lifeskim
pubmed-article:1361823lifeskim:mentionsumls-concept:C0031140lld:lifeskim
pubmed-article:1361823pubmed:dateCreated1993-2-2lld:pubmed
pubmed-article:1361823pubmed:abstractTextThe authors studied the effect of lovastatin on five hypercholesterolemic CAPD patients with high risk of atherosclerotic cardiovascular disease. Patients took lovastatin 20 mg once daily for a mean period of 4.5 months. Pre- and post-treatment values of LDL and VLDL totals (325 mg/dl and 292 mg/dl, respectively) and of HDL (42 mg/dl and 43 mg/dl, respectively) had no significant statistical difference. Lack of significance may be due to low number of patients and short trial time. The study did demonstrate that lovastatin is well tolerated in CAPD patients.lld:pubmed
pubmed-article:1361823pubmed:languageenglld:pubmed
pubmed-article:1361823pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1361823pubmed:citationSubsetIMlld:pubmed
pubmed-article:1361823pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1361823pubmed:statusMEDLINElld:pubmed
pubmed-article:1361823pubmed:issn1197-8554lld:pubmed
pubmed-article:1361823pubmed:authorpubmed-author:StarkeSSlld:pubmed
pubmed-article:1361823pubmed:authorpubmed-author:CaballeroMMlld:pubmed
pubmed-article:1361823pubmed:authorpubmed-author:KraneN KNKlld:pubmed
pubmed-article:1361823pubmed:authorpubmed-author:StockGGJrlld:pubmed
pubmed-article:1361823pubmed:issnTypePrintlld:pubmed
pubmed-article:1361823pubmed:volume8lld:pubmed
pubmed-article:1361823pubmed:ownerNLMlld:pubmed
pubmed-article:1361823pubmed:authorsCompleteYlld:pubmed
pubmed-article:1361823pubmed:pagination362-4lld:pubmed
pubmed-article:1361823pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1361823pubmed:meshHeadingpubmed-meshheading:1361823-...lld:pubmed
pubmed-article:1361823pubmed:meshHeadingpubmed-meshheading:1361823-...lld:pubmed
pubmed-article:1361823pubmed:meshHeadingpubmed-meshheading:1361823-...lld:pubmed
pubmed-article:1361823pubmed:meshHeadingpubmed-meshheading:1361823-...lld:pubmed
pubmed-article:1361823pubmed:meshHeadingpubmed-meshheading:1361823-...lld:pubmed
pubmed-article:1361823pubmed:meshHeadingpubmed-meshheading:1361823-...lld:pubmed
pubmed-article:1361823pubmed:meshHeadingpubmed-meshheading:1361823-...lld:pubmed
pubmed-article:1361823pubmed:meshHeadingpubmed-meshheading:1361823-...lld:pubmed
pubmed-article:1361823pubmed:year1992lld:pubmed
pubmed-article:1361823pubmed:articleTitleLovastatin in the treatment of hypercholesterolemia in CAPD.lld:pubmed
pubmed-article:1361823pubmed:affiliationTulane University School of Medicine, Department of Medicine, New Orleans, Louisiana.lld:pubmed
pubmed-article:1361823pubmed:publicationTypeJournal Articlelld:pubmed